At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 15 enrolled
Drug / intervention
Exenatide +1 moredrug
Likely dose
Exenatide 5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function
The University of Texas Health Science Center at San Antonio·interventional·Posted May 1, 2012·Updated Nov 24, 2017
In Brief
A Phase 4 clinical trial evaluating Exenatide and Placebo for Impaired Glucose Tolerance (IGT) and Diabetes. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This research study will examine brain glucose metabolism after an overnight fast to determine the effect of exenatide on brain glucose metabolism and lipid metabolism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImpaired Glucose Tolerance (IGT), Diabetes
CountriesUnited States
CollaboratorsAmylin Pharmaceuticals, LLC.
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedMay 2012
Primary CompletionJul 2015
TodayJul 2026
First PostedMay 1, 2012
Enrollment StartJul 1, 2010
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 14.2 years ago
Interventions
Exenatidedrug
Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
Placebodrug
Placebo was administered in random order 30 min before OGTT-PET study in the same subject